{
    "clinical_study": {
        "@rank": "11618", 
        "brief_summary": {
            "textblock": "To provide expanded access and to evaluate the safety, tolerability and efficacy of afatinib\n      in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring\n      Epidermal Growth Factor Receptor (EGFR) mutation(s) and have never been treated with an EGFR\n      tyrosine kinase inhibitor (TKI)"
        }, 
        "brief_title": "Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Carcinoma, Non-Small-Cell Lung", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. locally advanced or metastatic Non-Small Cell Lung Cancer\n\n          2. Epidermal Growth Factor Receptor mutation positive result per the institution's\n             testing methodology. Any type of EGFR mutation allowed\n\n          3. Treatment na\u00efve or patients who have received one line of chemotherapy, chemotherapy\n             include neo adjuvant and adjuvant chemotherapy within 1 year from enrolment\n\n          4. male or female patients age more than 18 years\n\n          5. Adequate organ function, defined as all of the following:\n\n               1. Absolute Neutrophil Count over 1500 per mm3. ANC over 1000 per mm3 may be\n                  considered in special circumstances such as benign cyclical neutropenia as\n                  judged by the investigator and in discussion with the sponsor.\n\n               2. Platelet count more than 75,000 per mm3\n\n               3. Serum creatinine below 1.5 times of the upper limit of normal\n\n               4. Total Bilirubin below 1.5 times upper limit of institutional normal. Patients\n                  with Gilbert's syndrome total bilirubin must be below 4 times institutional\n                  upper limit of normal.\n\n               5. Aspartate Amino Transferase or Alanine Amino Transferase below three times the\n                  upper limit of normal, if related to liver metastases below five times ULN.\n\n          6. ECOG score between 0 - 2\n\n          7. written informed consent by patient or guardian prior to admission into the trial\n             that is consistent with International Conference on Harmonisation - Good Clinical\n             Practice guidelines and local law.\n\n        Exclusion criteria:\n\n          1. prior treatment with an EGFR tyrosine kinase inhibitor\n\n          2. hormonal anti-cancer treatment within 2 weeks prior to start of trial treatment\n             ,continued use of anti androgens and or gonadorelin analogues for treatment of\n             prostate cancer permitted\n\n          3. radiotherapy within 14 days prior to drug administration, except as follows:\n\n               1. Palliative radiation to organs other than chest may be allowed up to 2 weeks\n                  prior to drug administration, and\n\n               2. Single dose palliative treatment for symptomatic metastasis outside above\n                  allowance to be discussed with sponsor prior to enrolling.\n\n          4. major surgery within 4 weeks before starting trial treatment or scheduled for surgery\n             during the projected course of the trial\n\n          5. known hypersensitivity to afatinib or any of its excipients\n\n          6. history or presence of clinically relevant cardiovascular abnormalities such as\n             uncontrolled hypertension, congestive heart failure New York Heart Association\n             classification of over 3, unstable angina or poorly controlled arrhythmia as\n             determined by the investigator. Myocardial infarction within 6 months prior to\n             starting trial treatment.\n\n          7. Women of Child-Bearing Potential and men who are able to father a child, unwilling to\n             use adequate contraception prior to trial entry, for the duration of trial\n             participation and for at least 2 weeks after treatment has ended.\n\n          8. childbearing potential who:\n\n               1. are nursing or\n\n               2. are pregnant or\n\n               3. are not using an acceptable method of birth control, or do not plan to continue\n                  using this method throughout the trial and,or do not agree to submit to\n                  pregnancy testing required by this protocol\n\n          9. any history of or concomitant condition that, in the opinion of the investigator,\n             would compromise the patient's ability to comply with the trial or interfere with the\n             evaluation of safety for the trial drug\n\n         10. previous or concomitant malignancies at other sites, except effectively treated\n             non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ\n             or effectively treated malignancy that has been in remission for more than 3 years\n             and is considered to be cured.\n\n         11. requiring treatment with any of the prohibited concomitant medications that can not\n             be stopped for the duration of trial participation\n\n         12. known pre-existing interstitial lung disease\n\n         13. presence of poorly controlled gastrointestinal disorders that could affect the\n             absorption of the trial drug\n\n         14. active hepatitis B infection, active Hepatitis C infection\n\n         15. meningeal carcinomatosis\n\n         16. symptomatic brain metastases, patients with asymptomatic brain metastases, who were\n             previously treated, are eligible provided they have had Stable Disease for at least 4\n             weeks on stable doses of medication"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "August 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01931306", 
            "org_study_id": "1200.193"
        }, 
        "intervention": {
            "description": "BIBW2992 low to medium dose once daily", 
            "intervention_name": "Afatinib", 
            "intervention_type": "Drug"
        }, 
        "lastchanged_date": "May 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bucheon", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "1200.193.82003 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Busan", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "1200.193.82009 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Incheon", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "1200.193.82001 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jeonnam", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "1200.193.82010 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jinju", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "1200.193.82002 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seongnam", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "1200.193.82004 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "1200.193.82007 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "1200.193.82008 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "1200.193.82005 Boehringer Ingelheim Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "1200.193.82006 Boehringer Ingelheim Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "official_title": "An Open Label Expanded Access Program of Afatinib (BIBW 2992) in Treatment-naive or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Available", 
        "oversight_info": {
            "authority": "South Korea: Ministry of Food and Drug Safety (MFDS)"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01931306"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "N/A", 
        "study_type": "Expanded Access", 
        "verification_date": "May 2014"
    }
}